Astria Therapeutics, Inc. (NASDAQ:ATXS) Sees Large Growth in Short Interest

Astria Therapeutics, Inc. (NASDAQ:ATXS) was the target of a significant growth in short interest during the month of November. As of November 30th, there was short interest totalling 3,150,000 shares, a growth of 8.6% from the November 15th total of 2,900,000 shares. Based on an average daily volume of 321,400 shares, the days-to-cover ratio is currently 9.8 days. Currently, 6.5% of the shares of the stock are short sold.

Wall Street Analysts Forecast Growth

ATXS has been the topic of a number of recent research reports. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 target price on shares of Astria Therapeutics in a research note on Tuesday, December 10th. Oppenheimer upped their price objective on Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a research report on Thursday, November 14th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Astria Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $25.60.

Hedge Funds Weigh In On Astria Therapeutics

Several institutional investors have recently added to or reduced their stakes in ATXS. Barclays PLC grew its holdings in Astria Therapeutics by 70.5% in the 3rd quarter. Barclays PLC now owns 92,651 shares of the biotechnology company’s stock valued at $1,020,000 after buying an additional 38,321 shares during the period. Wellington Management Group LLP grew its holdings in Astria Therapeutics by 8.7% in the third quarter. Wellington Management Group LLP now owns 147,499 shares of the biotechnology company’s stock valued at $1,624,000 after purchasing an additional 11,763 shares during the period. RA Capital Management L.P. increased its position in Astria Therapeutics by 1.2% during the third quarter. RA Capital Management L.P. now owns 5,105,213 shares of the biotechnology company’s stock worth $56,208,000 after purchasing an additional 61,457 shares during the last quarter. Redmile Group LLC purchased a new position in Astria Therapeutics during the third quarter worth approximately $3,423,000. Finally, Patient Square Capital LP acquired a new position in shares of Astria Therapeutics in the 3rd quarter valued at $434,000. 98.98% of the stock is currently owned by institutional investors and hedge funds.

Astria Therapeutics Stock Performance

NASDAQ ATXS traded down $0.29 during mid-day trading on Friday, reaching $9.52. 195,675 shares of the stock were exchanged, compared to its average volume of 593,820. Astria Therapeutics has a 1-year low of $5.80 and a 1-year high of $16.90. The stock has a market capitalization of $537.21 million, a PE ratio of -4.56 and a beta of 0.67. The business’s fifty day simple moving average is $10.82 and its 200 day simple moving average is $10.69.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.